UPDATES
1
2
3
4
5
6
7
8
9
Acknowledgements
This work was supported by the Agence Nationale de la
Recherche (projet NIPS ANR JCJC, n8 ANR-12-JS07-0008-
01, grant to JSS). RMF and JMC gratefully thank the CNRS
and the ENSCM. Lindsay Mas-Normand (undergraduate
student on practical training) is kindly thanked for her help
with the gram-scale synthesis of compound 4a. The authors
give special thanks to Pascale Guiffrey (responsible of the
analytical platform of the team) for her support.
Scheme 4. Sequential, one-pot gram-scale synthesis of dipep-
tide Boc-Phe-Ala-OMe (4a).
10
11
12
References
In summary, the synthesis of several dipeptides and
13 a tripeptide through in situ generated CDI-protected
14 a-amino esters based on an inverse activation mode
15 has been successfully achieved. The devised one-pot
16 procedure, improved from the former studies from
17 our laboratories, provides a much easier, practical and
18 cost-effective method to access dipeptides (12 exam-
19 ples) in good yields (up to 87%) and with complete
20 absence of epimerization. Due to the growing interest
21 for peptides in pharmaceuticals and the ever growing
22 need for novel strategies seeking to the amide bond
23 formation, this sequential one-pot process affords a
24 good and reliable alternative that could be added to
25 the challenging non-conventional methods towards
26 amides for peptide bond formation.
[1] a) J. S. Carey, D. Laffan, C. Thomson, M. T. Williams,
Org. Biomol. Chem. 2006, 4, 2337; b) A. K. Ghose, V. N.
Viswanadhan, J. J. Wendoloski, J. Comb. Chem. 1999, 1,
55; c) “Therapeutic Peptides under the Spotlight”: C.
Pichereau, C. Allary, in European Biopharmaceutical
Review (EBR), January 2005; d) V. Marx, Chem. Eng.
News 2005, 83, 17; e) L. M. Jarvis, Chem. Eng. News
2006, 84, 23; f) P. Vlieghe, V. Lisowski, J. Martinez, M.
Khrestchatisky, Drug Discovery Today 2010, 15, 40;
e) A. Sharman, S. Arora, Res. J. Pharm., Biol. Chem.
Sci. 2011, 2, 778.
[2] D. J. Craik, D. P. Fairlie, S. Liras, D. Price, Chem. Biol.
Drug. Des. 2013, 81, 136.
[3] T. Uhlig, T. Kyprianou, F. G. Martinelli, C. A. Oppici, D.
Heiligers, D. Hills, X. R. Calvo, P. Verhaert, EuPA
Open Proteomics 2014, 4, 58.
[4] K. Fosgerau, T. Hoffmann, Drug Disc. Today 2015, 20,
122.
27
28
29
Experimental Section
30 Typical Procedure for the Sequential One-Pot Syn-
31 thesis of Dipeptides (4) through the in situ Formation
32 of CDI-N-Protected a-Aminoesters (2)
[5] S. D. Roughley, A. M. Jordan, J. Med. Chem. 2011, 54,
3451.
[6] For selected reviews, see: a) F. Albericio, R. Chinchilla,
D. J. Dodsworth, C. Nꢁjera, Org. Prep. Proc. Int. 2001,
33, 203; b) S.-Y. Han, Y.-A. Kim, Tetrahedron 2004, 60,
2447; c) C. A. G. N. Montalbetti, V. Falque, Tetrahedron
2005, 61, 10827; d) E. Valeur, M. Bradley, Chem. Soc.
Rev. 2009, 38, 606; e) A. El-Faham, F. Albericio, Chem.
Rev. 2011, 111, 6557; f) M. M. Joulliꢂ, K. M. Lassen,
ARKIVOC 2010, 189; g) J. R. Dunetz, J. Magano, G. A.
Weisenburger, Org. Process Res. Dev. 2016, 20, 140;
h) T. I. Al-Warhi, H. M. A. Al-Hazimi, A. El-Faham, J.
Saudi Chem. Soc. 2012, 16, 97; i) R. M. Lanigan, T. D.
Sheppard, Eur. J. Org. Chem. 2013, 7453.
[7] For selected recent reviews, see: a) J. W. Bode, Curr.
Opin. Drug Discovery Dev. 2006, 9, 765; b) V. R.
Pattabiraman, J. W. Bode, Nature 2011, 480, 471;
c) R. M. de Figueiredo, J.-S. Suppo, J.-M. Campagne,
Chem. Rev. 2016, 116, 12029; d) A. Ojeda-Porras, D.
Gamba-Sꢁnchez, J. Org. Chem. 2016, 81, 11548.
[8] a) S. T. Heller, R. Sarpong, Org. Lett. 2010, 12, 4572;
b) S. T. Heller, T. Fu, R. Sarpong, Org. Lett. 2012, 14,
1970.
33
34
35
36
37
38
To a suspension of CDI (0.75 mmol, 1.5 equiv.) in CH2Cl2 (c
1 M, stabilized with amylene) was added HCl·H2N-AA1-OR
(0.75 mmol, 1.5 equiv.) and the resulting suspension was
stirred for 30 min at ambient temperature (21–248C). The
transient formation of CDI-N-protected a-aminoesters (2)
could be monitored by TLC. Then, to the reaction mixture
39 was successively added PHN-AA2-CO2H (0.50 mmol,
1.0 equiv.), HOBt (0.05 mmol, 10 mol%) and CuBr2
(0.05 mmol, 10 mol%). The resulting blue suspension so
obtained was then stirred at ambient temperature (21–248C)
for additional 20 h. After reaction completion (TLC monitor-
ing), the mixture was diluted with CH2Cl2 (10 mL) and
washed once with aqueous HCl 1.0 N (10 mL). The aqueous
phase was further extracted with CH2Cl2 (10 mL). The
organic layers were combined and washed once with a
saturated aqueous solution of NaHCO3 (10 mL). The organic
phase was separated and then washed with brine (10 mL).
Afterwards, the organic layer was dried over MgSO4, filtered
and concentrated under reduced pressure. Crude NMR of
the compounds after this classical work-up, showed the
expected dipeptides with excellent purity; only a small
amount of symmetrical ureas (<5%) could be observed in
some cases. Purification was performed by simple filtration
on a short pad of silica gel by using a mixture of pentane/
EtOAc as eluent. Dipeptides 4 were isolated as white foams
or solids.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
[9] R. Paul, G. W. Anderson, J. Am. Chem. Soc. 1960, 82,
4596.
[10] For the use of N-methyl imidazolium salt derivatives in
the synthesis of ureas, thioureas, carbamates, thiocarba-
mates and amides, see: a) R. A. Batey, V. Santhakumar,
C. Yoshina-Ishii, S. D. Taylor, Tetrahedron Lett. 1998,
Adv. Synth. Catal. 2017, 359, 1–7
5
ꢀ 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ÞÞ
These are not the final page numbers!